Could This Stock Be the Next Biotech Buyout?
The biotechnology industry is getting more attention than usual following a buyout offer for Alpine Immune Sciences (NASDAQ: ALPN) from Vertex Pharmaceuticals (NASDAQ: VRTX).
Vertex recently offered Alpine Immune Sciences $65 per share, or about $4.9 billion in cash. On April 9, the day before the announcement, Alpine's stock price closed at about $39 per share.
Government regulators rarely try to prevent big pharmaceutical companies from acquiring clinical-stage biotechs. This means Alpine shareholders will most likely see their investment increase by about 67% when the deal closes, probably in a couple of months.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
447,70 €
-0,06 %
Starkes Buy-Sentiment bei Vertex Pharmaceuticals Inc. mit 42 Buy- gegenüber 1 Sell-Einschätzungen.
Ein positives, wenn auch nicht starkes, Potenzial für Vertex Pharmaceuticals Inc. mit einem Kursziel von 474 € im Vergleich zu 447.7 €.
